Market Place
Sourcing Support
Biogen`s rare genetic disorder drug gets approval in EU
13 Feb 2024 //
FIERCE PHARMA
Biogen`s Skyclarys backed by EU panel for Friedreich`s ataxia
16 Dec 2023 //
GLOBENEWSWIRE
Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio
29 Jul 2023 //
HEALTH ET
Biogen to Acquire Reata Pharmaceuticals
28 Jul 2023 //
GLOBENEWSWIRE
Plano-based Reata Pharmaceuticals launches its first drug, Skyclarys
29 Jun 2023 //
DALLASNEWS
Reata Pharma Announces Approval of Prior Approval Supplement for SKYCLARY
27 Jun 2023 //
BUSINESSWIRE
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS®
15 Jun 2023 //
BUSINESSWIRE
FDA signs off on Reata`s Skyclarys for rare neurologic disorder
02 Mar 2023 //
FIERCE PHARMA
Reata has wait for FDA ataxia drug decision delayed by 3 months
10 Aug 2022 //
FIERCEBIOTECH
Karuna`s schizophrenia drug passes PhIII test, will head to FDA in mid-2023
09 Aug 2022 //
ENDPTS
Reata Pharma to Report 2nd Quarter 2022 Financial Results
01 Aug 2022 //
BUSINESSWIRE
Reata`s Rolling Submission of NDA for Omaveloxolone in Friedreich’s Ataxia
31 Mar 2022 //
BUSINESSWIRE
Reata Initiates Rolling Submission of NDA with FDA for Omaveloxolone
31 Jan 2022 //
BUSINESSWIRE
FDA Grants FTD to Reata`s Omaveloxolone for Friedreich’s Ataxia
18 Nov 2021 //
BUSINESSWIRE
Reata Pharmaceuticals NDA Submission for Omaveloxolone in First Quarter of 2022
30 Sep 2021 //
BUSINESSWIRE
Reata Provides Update on Omaveloxolone Program for Patients
24 Nov 2020 //
GLOBENEWSWIRE
Reata suggests Friedreich`s ataxia program could be delayed, sending stock plunging
11 Aug 2020 //
ENDPTS
Reata shocks analysts with pivotal win in Friedreich`s ataxia
16 Oct 2019 //
FIERCE BIOTECH
Reata`s omaveloxolone successful in mid-stage FA study
14 Oct 2019 //
SEEKINGAPLPHA
Reata Receives Orphan from the EU for Omaveloxolone Friedreich’s Ataxia
10 Jul 2018 //
PRESS RELEASE
Reata`s Announces Closing of Class A Common Stock Public Offering
27 Jun 2018 //
PRESS RELEASE
Reata Announces New Preclinical Data Demonstrating , Potential of Omaveloxolone
24 Apr 2018 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.